(11–13)], involvement of viral inhibitors like the SV40 small T antigen (14–17), or activation of cellular inhibitors such as SET or CIP2A, the former of which is induced by BCR–ABL in chronic myeloid leukemia [CML; (18–23)]. This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.